What are the early warning signs of myocarditis during the pathway of care?

IF 1.8 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Expert Review of Cardiovascular Therapy Pub Date : 2024-10-01 Epub Date: 2024-10-24 DOI:10.1080/14779072.2024.2416676

Yasar Sattar, Aimen Shafiq, Sahithi Sharma, Krutarth Pandya, Karthik Gonuguntla, Harshith Thyagaturu, Fnu Zafrullah, Sudarshan Balla

{"title":"What are the early warning signs of myocarditis during the pathway of care?","authors":"Yasar Sattar, Aimen Shafiq, Sahithi Sharma, Krutarth Pandya, Karthik Gonuguntla, Harshith Thyagaturu, Fnu Zafrullah, Sudarshan Balla","doi":"10.1080/14779072.2024.2416676","DOIUrl":null,"url":null,"abstract":"Introduction: Myocarditis is an inflammatory disease of the myocardial layer of the heart that can be prone to dilation of chambers with presentation as heart failure secondary to dilated cardiomyopathy. Myocarditis can lead to remodeling and fibrosis that can affect the heart's relaxation-lusitropy and chronotropic function. The current techniques for identifying myocarditis, such as endomyocardial biopsy and imaging, are costly, and intrusive. The current literature aims to identify reliable, accurate, and prognostically educative biomarkers of myocarditis.Areas covered: This review covers the definition, clinical features, diagnostic markers, cardiac imaging, prognosis, and complications of myocarditis. PubMed, Embase, and the Cochrane data bank were searched from inception to 1 January 2024 for relevant articles.Expert opinion: By adopting these diagnostic and prognostic biomarkers, clinicians can have a better comprehension of the progression of the disease and provide early diagnosis and treatment for myocarditis.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"553-563"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Cardiovascular Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14779072.2024.2416676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Myocarditis is an inflammatory disease of the myocardial layer of the heart that can be prone to dilation of chambers with presentation as heart failure secondary to dilated cardiomyopathy. Myocarditis can lead to remodeling and fibrosis that can affect the heart's relaxation-lusitropy and chronotropic function. The current techniques for identifying myocarditis, such as endomyocardial biopsy and imaging, are costly, and intrusive. The current literature aims to identify reliable, accurate, and prognostically educative biomarkers of myocarditis.

Areas covered: This review covers the definition, clinical features, diagnostic markers, cardiac imaging, prognosis, and complications of myocarditis. PubMed, Embase, and the Cochrane data bank were searched from inception to 1 January 2024 for relevant articles.

Expert opinion: By adopting these diagnostic and prognostic biomarkers, clinicians can have a better comprehension of the progression of the disease and provide early diagnosis and treatment for myocarditis.

查看原文本刊更多论文

在治疗过程中，心肌炎有哪些早期预警信号？

简介心肌炎是心脏心肌层的一种炎症性疾病，容易导致心腔扩张，表现为继发于扩张型心肌病的心力衰竭。心肌炎可导致心肌重塑和纤维化，从而影响心脏的松弛-松弛功能和时变功能。目前用于鉴别心肌炎的技术，如心内膜活检和成像，成本高昂且具有侵入性。目前的文献旨在确定可靠、准确且对预后有帮助的心肌炎生物标志物：本综述涵盖心肌炎的定义、临床特征、诊断标志物、心脏成像、预后和并发症。在PubMed、Embase和Cochrane数据库中搜索了从开始到2024年1月1日的相关文章：通过采用这些诊断和预后生物标志物，临床医生可以更好地了解疾病的进展情况，为心肌炎提供早期诊断和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Cardiovascular Therapy CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

3.70

自引率

0.00%

发文量

期刊介绍： Expert Review of Cardiovascular Therapy (ISSN 1477-9072) provides expert reviews on the clinical applications of new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage includes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery. The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of research or clinical practice.